Heidelberg University

European Wellness Leads Pioneering Down Syndrome Research at Heidelberg University

Retrieved on: 
Thursday, April 18, 2024
Education, Heidelberg University, Down syndrome, Quality of life, Research, MRI, Pharmaceutical industry

HEIDELBERG, Germany, April 18, 2024 /PRNewswire/ -- The European Wellness Biomedical Group (EWBG), in collaboration with the European Wellness Academy (EWA), the Baden Research Lab, and Heidelberg University, has announced substantial advances in Down Syndrome research, revealing new neuroanatomical insights that open the way for novel care methods.

Key Points: 
  • HEIDELBERG, Germany, April 18, 2024 /PRNewswire/ -- The European Wellness Biomedical Group (EWBG), in collaboration with the European Wellness Academy (EWA), the Baden Research Lab, and Heidelberg University, has announced substantial advances in Down Syndrome research, revealing new neuroanatomical insights that open the way for novel care methods.
  • EWBG, known for its groundbreaking work in stem cell therapy, has been at the forefront of this study, working closely with Heidelberg University.
  • Meanwhile, Baden concentrates on creating a conducive research environment while Heidelberg University grows as a global leader in stem cell research and immunology, advancing the study's goals.
  • This joint project is a watershed moment in Down Syndrome research, setting a new standard for tackling and treating complicated neurological illnesses.

European Wellness Leads Pioneering Down Syndrome Research at Heidelberg University

Retrieved on: 
Thursday, April 18, 2024
Education, Heidelberg University, Down syndrome, Research, MRI, Multimedia, Quality of life, Pharmaceutical industry

HEIDELBERG, Germany, April 18, 2024 /PRNewswire/ -- The European Wellness Biomedical Group (EWBG), in collaboration with the European Wellness Academy (EWA), the Baden Research Lab, and Heidelberg University, has announced substantial advances in Down Syndrome research, revealing new neuroanatomical insights that open the way for novel care methods.

Key Points: 
  • HEIDELBERG, Germany, April 18, 2024 /PRNewswire/ -- The European Wellness Biomedical Group (EWBG), in collaboration with the European Wellness Academy (EWA), the Baden Research Lab, and Heidelberg University, has announced substantial advances in Down Syndrome research, revealing new neuroanatomical insights that open the way for novel care methods.
  • EWBG, known for its groundbreaking work in stem cell therapy, has been at the forefront of this study, working closely with Heidelberg University.
  • Meanwhile, Baden concentrates on creating a conducive research environment while Heidelberg University grows as a global leader in stem cell research and immunology, advancing the study's goals.
  • This joint project is a watershed moment in Down Syndrome research, setting a new standard for tackling and treating complicated neurological illnesses.

Blue Faery Awards Liver Cancer Research Grant

Retrieved on: 
Monday, April 8, 2024
HCC, Research, Fairy, Internal medicine, Liver cancer, AstraZeneca, Professor, Caregiver, Patient, Education, Hepatocellular carcinoma, Heidelberg University, Culture, Teaching hospital, University of Marburg, Neoplasm, Cancer, LOS, Gastrointestinal disease, Multimedia, BFA

LOS ANGELES, April 8, 2024 /PRNewswire/ -- Blue Faery: The Adrienne Wilson Liver Cancer Association announces the annual Blue Faery Award (BFA) for Excellence in Liver Cancer Research. Primary liver cancer, also known as Hepatocellular Carcinoma (HCC), is the third leading cause of cancer deaths worldwide. Blue Faery created the award to recognize medical professionals who do innovative HCC research.

Key Points: 
  • Dr. Peter Galle, Professor and Chairman at University Medical Center Mainz, wins a $25K grant
    LOS ANGELES, April 8, 2024 /PRNewswire/ -- Blue Faery: The Adrienne Wilson Liver Cancer Association announces the annual Blue Faery Award (BFA) for Excellence in Liver Cancer Research.
  • Blue Faery's mission is to prevent, treat, and cure primary liver cancer through research, education, and advocacy.
  • Blue Faery provides free comprehensive patient education with its Patient Resource Guides for Liver Cancer .
  • Blue Faery has three public education and awareness programs: Love Your Liver, The Truth About Liver Cancer, and You and Liver Cancer.

Astonishing brain tumour research wins the BIAL Award in Biomedicine 2023 worth 300,000 Euro

Retrieved on: 
Wednesday, February 21, 2024
Nobel Prize, Bial, University of Glasgow, Messenger, Synapse, Teaching hospital, Glioblastoma, Neuron, Neoplasm, Thought, University Hospital Heidelberg, University of Bergen, Vaccine, University, Haukeland University Hospital, COVID-19, Memory, Glioma, Jury, Heidelberg University, University Hospital Mannheim, Brain, Epilepsy, Tissue, Research, German Cancer Research Center, Medical imaging

This is possible by formation of synapses between neurons and cancer cells.

Key Points: 
  • This is possible by formation of synapses between neurons and cancer cells.
  • This paper shows that cancer cells cannot merely proliferate - they have to hijack healthy biological processes and integrate themselves into the normal function of tissues.
  • "Nowhere is this more blatant - and surprising - than in the brain tumours studied in this paper", says Ralph Adolphs.
  • The award-winning research also provides a new explanation for why epilepsy and tumour progression are often observed together: epilepsy may be a cause, rather than a consequence of the tumour progression.

Astonishing brain tumour research wins the BIAL Award in Biomedicine 2023 worth 300,000 Euro

Retrieved on: 
Wednesday, February 21, 2024
Nobel Prize, Bial, University of Glasgow, Messenger, Synapse, Teaching hospital, Glioblastoma, Neuron, Neoplasm, Thought, University Hospital Heidelberg, University of Bergen, Vaccine, University, Haukeland University Hospital, COVID-19, Memory, Glioma, Jury, Heidelberg University, University Hospital Mannheim, Brain, Epilepsy, Tissue, Research, German Cancer Research Center, Medical imaging

This is possible by formation of synapses between neurons and cancer cells.

Key Points: 
  • This is possible by formation of synapses between neurons and cancer cells.
  • This paper shows that cancer cells cannot merely proliferate - they have to hijack healthy biological processes and integrate themselves into the normal function of tissues.
  • "Nowhere is this more blatant - and surprising - than in the brain tumours studied in this paper", says Ralph Adolphs.
  • The award-winning research also provides a new explanation for why epilepsy and tumour progression are often observed together: epilepsy may be a cause, rather than a consequence of the tumour progression.

Fusion Pharmaceuticals Enters into Exclusive Worldwide License Agreement with Heidelberg University and Euratom for Actinium-Based PSMA Targeted Radiotherapy

Retrieved on: 
Friday, February 16, 2024
European Commission, Fusion, Cancer, Food, PSMA, Patent, Civil service commission, Heidelberg University, Patient, Joint Research Centre, Radiation, Pharmaceutical industry

HAMILTON, ON and BOSTON, Feb. 16, 2024 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that it has entered into an exclusive worldwide license agreement with Heidelberg University and Euratom represented by the European Commission, Joint Research Centre (together, the "Licensors"). The license agreement grants Fusion exclusive worldwide rights to utilize, develop, manufacture and commercialize compounds covered by the patent, which includes 225Ac-PSMA I&T ("FPI-2265") for the treatment of prostate specific membrane antigen (PSMA)-expressing cancers. In addition, Fusion and the Licensors have signed an agreement to settle the parties' dispute related to an inter partes review ("IPR") of a U.S. patent owned by the Licensors which was instituted in August 2023 by the United States Patent and Trademark Board.

Key Points: 
  • HAMILTON, ON and BOSTON, Feb. 16, 2024 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that it has entered into an exclusive worldwide license agreement with Heidelberg University and Euratom represented by the European Commission, Joint Research Centre (together, the "Licensors").
  • The license agreement grants Fusion exclusive worldwide rights to utilize, develop, manufacture and commercialize compounds covered by the patent, which includes 225Ac-PSMA I&T ("FPI-2265") for the treatment of prostate specific membrane antigen (PSMA)-expressing cancers.
  • Fusion President and Chief Business Officer Mohit Rawat said, "We are pleased to enter into this exclusive license agreement with Heidelberg University and Euratom for their existing patent as we progress FPI-2265, the most advanced actinium-based PSMA targeted radiotherapy currently in development.
  • Under the terms of the license agreement, Fusion will pay the Licensors an aggregate upfront fee of €1.0 million, in addition to certain regulatory milestones upon potential approval and low single-digit royalties on future net sales of applicable products.

FundaMental Pharma GmbH announces publication of a groundbreaking Proof-of-Concept Study in Cell Reports Medicine using a TwinF Interface Inhibitor for the Treatment of Amyotrophic Lateral Sclerosis

Retrieved on: 
Wednesday, February 7, 2024
Mortality, Heidelberg University, ALS, Research, Fundamental, NMDA, Patient, Excitotoxicity, Yan, TRPM4, Pharmaceutical industry

Heidelberg, Germany, 7 February 2024 – FundaMental Pharma GmbH (‘FundaMental’ or ’the Company’), a neuroscience company developing first-in-class small molecule inhibitors for treatment of a range of neurodegenerative diseases, today announces the publication of a groundbreaking study by Neurobiologists in Heidelberg using FundaMental Pharma’s small molecule TwinF interface inhibitor, FP802.

Key Points: 
  • Heidelberg, Germany, 7 February 2024 – FundaMental Pharma GmbH (‘FundaMental’ or ’the Company’), a neuroscience company developing first-in-class small molecule inhibitors for treatment of a range of neurodegenerative diseases, today announces the publication of a groundbreaking study by Neurobiologists in Heidelberg using FundaMental Pharma’s small molecule TwinF interface inhibitor, FP802.
  • The study provides seminal preclinical proof-of-concept data for the treatment of amyotrophic lateral sclerosis (ALS).
  • Most importantly, the validated ALS clinical biomarker neurofilament light chain (Nf-L) was reduced in line with the positive treatment effects.
  • TwinF interface inhibitors constitute an entirely new class of drugs that safely ameliorate glutamate neurotoxicity, a common cause of neurodegeneration.

HOOKIPA Pharma Appoints Mark Winderlich as Chief Development Officer to Lead Clinical Research and Development Organization

Retrieved on: 
Tuesday, January 16, 2024
Bristol Myers Squibb, Partnership, Standard of care, Heidelberg University, Arenavirus, Head, MorphoSys, Drug development, Doctor of Philosophy, Master of Science, Max Planck Society, Management

Dr. Winderlich has rich experience leading multiple candidates through the drug development process to product approval in the United States and in Europe.

Key Points: 
  • Dr. Winderlich has rich experience leading multiple candidates through the drug development process to product approval in the United States and in Europe.
  • “We are pleased to bring our search for a capable clinical development leader to such a swift, successful resolution and welcome Mark to the team,” said Joern Aldag, Chief Executive Officer at HOOKIPA.
  • “Mark is a tremendous talent with rich experience across the drug development lifecycle.
  • Prior to Evotec, Dr. Winderlich spent more than 12 years in drug development at MorphoSys AG across various roles of increasing responsibility.

Enterome Appoints Industry Veteran Dr. Peter Hirth to its Board of Directors

Retrieved on: 
Monday, December 18, 2023
Biotechnology, Drug development, Molecular genetics, Research, FDA, Inflammation, Roche, Doctor of Philosophy, Heidelberg University, Therapy, Gastrointestinal cancer, Plexxikon, University, Max Planck Society, Wellington Partners, Growth, Patient

"We are delighted to welcome Peter to Enterome's Board of Directors," said Dr. Pierre Bélichard, Chief Executive Officer of Enterome.

Key Points: 
  • "We are delighted to welcome Peter to Enterome's Board of Directors," said Dr. Pierre Bélichard, Chief Executive Officer of Enterome.
  • "Peter is a recognized leader in the biotech industry and his extensive experience in corporate strategy and drug development will be invaluable to Enterome’s future growth and success.
  • I’d also like to thank Roger for his invaluable contributions to Enterome during his time on the Board."
  • Dr. Hirth possesses a wealth of experience and an exceptional track record in the biopharmaceutical industry.

European Wellness and DXN Sign MoU to Establish World-Class Wellness Centre!

Retrieved on: 
Thursday, November 9, 2023
BWA, Health, International trade, Therapy, EW Group, Food, Myco, Heidelberg University, Research, DXN, Economic development, University, Marketing, Partnership, Plant, Immunomodulation, Hospital, KSI, Peptide, B cell, Pharmaceutical industry

CYBERJAYA, Malaysia, Nov. 9, 2023 /PRNewswire/ -- European Wellness Biomedical Group (EW Group) has signed a Memorandum of Understanding with DXN Holdings Berhad (DXN) to jointly develop and establish a comprehensive wellness centre that draws from the extensive expertise and experience of both parties.

Key Points: 
  • CYBERJAYA, Malaysia, Nov. 9, 2023 /PRNewswire/ -- European Wellness Biomedical Group (EW Group) has signed a Memorandum of Understanding with DXN Holdings Berhad (DXN) to jointly develop and establish a comprehensive wellness centre that draws from the extensive expertise and experience of both parties.
  • Their goals align with DXN, one of the most established and globalised publicly-listed Malaysian companies in researching, producing, and marketing organic health and wellness products.
  • Together, they are in pole position to revolutionise the health and wellness industry.
  • A multi-award-winning European group comprising of multinational business divisions collectively operating in the emerging fields of bio-regenerative medicine.